SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: CYBERKEN who wrote (23942)8/5/1998 7:06:00 AM
From: Henry Niman  Respond to of 32384
 
Panretin and Targretin trials are both Phase II. Phase I trials are generally for safety, while Phase II trials are for optimal dose. The Panretin trials have been completed and Targretin are wrapping up. I think that LGND started these trials at the higher doses that are used for cancer treatments. The drugs worked, but now they are trying to see how low they can go, to get a response with the psoriasis, without elevated triglycerides.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News